{"filings":[{"id":778758,"accession_number":"0001689548-26-000053","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2026-06-01T20:28:49+00:00","items":["8.01"],"status":"ready","headline":"Praxis Precision Medicines: Phase 2/3 vormatrigine study fails primary endpoint in focal seizures","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["POWER1 study of vormatrigine in focal onset seizures did not meet primary success measure.","Secondary 50% response rate achieved; higher 30 mg dose showed more pronounced seizure reduction in second half.","Vormatrigine well-tolerated with <10% adverse event-related discontinuations; ~90% entered open-label extension.","Company pausing enrollment in POWER2 study to reassess vormatrigine program and potential modifications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68485,"accession_number":"0001689548-26-000049","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2026-05-13T20:16:30+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Praxis reports Q1 net loss of $92.6M; FDA accepts NDAs for ulixacaltamide and relutrigine","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA accepted NDA for ulixacaltamide (Essential Tremor) with PDUFA Jan 29, 2027; relutrigine NDA (SCN2A/SCN8A DEEs) granted priority review with PDUFA Sept 27, 2026.","Cash and investments $1.4B as of Mar 31, 2026, up from $926.1M Dec 2025; funded into 2028.","Net loss $92.6M vs $69.3M in Q1 2025; R&D expenses $78.0M (up $17.2M YoY); G&A $27.9M (up $14.0M YoY).","EMBRAVE Part A: elsunersen showed 77% placebo-adjusted seizure reduction; 71% patients achieved >50% reduction.","Topline POWER1 (vormatrigine in FOS) expected Q2 2026; EMERALD (relutrigine in broad DEEs) topline Q4 2026."],"consensus_eps_estimate":-3.6202,"consensus_eps_actual":-3.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94698,"accession_number":"0001689548-26-000033","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Praxis Precision: FDA accepts NDA for ulixacaltamide in essential tremor; PDUFA Jan 29, 2027","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted NDA for ulixacaltamide HCl to treat essential tremor in adults; PDUFA target action date January 29, 2027.","No advisory committee meeting will be held for the ulixacaltamide NDA review.","The NDA seeks approval for a novel small-molecule therapy for a common movement disorder."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94697,"accession_number":"0001689548-26-000031","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Praxis reports positive EMBRAVE Part A data for elsunersen; FDA grants priority review for relutrigine","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elsunersen achieved 77% placebo-adjusted seizure reduction (p=0.015) in 9-patient Phase 1/2 trial.","57% of elsunersen patients had ≥28-day seizure freedom; improvements in sleep, motor function, attention.","Relutrigine NDA accepted for priority review by FDA with PDUFA target date of September 27, 2026.","Elsunersen well tolerated; no drug-related SAEs, no discontinuations, no neuroinflammation at doses up to 8 mg.","All 9 patients continued into open-label extension; efficacy sustained for up to one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107278,"accession_number":"0001689548-26-000028","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Praxis reports Q4 net loss $88.9M; submits two NDAs; cash $926M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $88.9M in Q4 2025 ($303.3M FY), vs $58.7M ($182.8M FY) prior year.","Cash and investments $926.1M at Dec 31, 2025; plus $621.2M Jan 2026 offering funds operations into 2028.","Submitted NDAs to FDA for ulixacaltamide (essential tremor) and relutrigine (SCN2A/SCN8A DEEs).","Topline results expected H1 2026 for vormatrigine Phase 3 (POWER1) and elsunersen EMBRAVE Part A.","Board additions: Jeffrey Kindler, Stuart Arbuckle; promoted Sniecinski to COO, Petrou to President R&D."],"consensus_eps_estimate":-3.1625,"consensus_eps_actual":-13.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107274,"accession_number":"0001689548-26-000016","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K/A","filed_at":"2026-02-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Praxis assigns Kindler to Audit/Nominating, Arbuckle to Comp/Science & Tech; amends director comp policy","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey B. Kindler appointed to Audit Committee and Nominating and Corporate Governance Committee effective Feb 6, 2026.","Stuart A. Arbuckle appointed to Compensation Committee and Science and Technology Committee effective Feb 6, 2026.","Board amended Non-Employee Director Compensation Policy; cash retainers: $50k board, $40k chair, plus committee chair/member fees.","New directors received initial RSUs ($220k) and pro-rata option/RSUs; annual awards: $110k option + $330k RSU for continuing directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107277,"accession_number":"0001689548-26-000005","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Praxis promotes Sniecinski to COO; adds Kindler and Arbuckle to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Megan Sniecinski promoted to COO effective Jan 1, 2026; previously CBO since Dec 2021.","Sniecinski's base salary increased to $626,000, target bonus 50% of salary for 2026.","Jeffrey B. Kindler elected to Board as Class II director, effective Jan 8, 2026; deemed independent.","Stuart A. Arbuckle elected to Board as Class II director, effective Jan 8, 2026; deemed independent.","Kindler and Arbuckle entitled to initial stock option awards and annual retainers per company policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107276,"accession_number":"0001104659-26-001825","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Praxis Precision Medicines prices $661M equity offering at $260/share, net proceeds ~$621M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 2,212,000 shares plus full exercise of underwriter option for 331,800 shares at $260/share.","Net proceeds estimated at $621.2M after underwriting discounts and expenses.","Underwriters: Piper Sandler, TD Securities, Guggenheim Securities; closing expected Jan 8, 2026.","Proceeds to fund commercialization prep, R&D, and working capital; cash runway extended into 2028.","Offering made under effective shelf registration (Form S-3 ASR filed Dec 23, 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107275,"accession_number":"0001689548-26-000002","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Praxis reports prelim. cash of ~$925M as of Dec 31, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities approx. $925M as of Dec 31, 2025.","Data is preliminary, unaudited, and subject to completion of year-end closing procedures.","No other financial results (revenue, EPS) were disclosed; company is a pre-revenue biotech.","Independent auditor has not expressed an opinion on this preliminary estimate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123626,"accession_number":"0001689548-25-000118","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"PRAX gets FDA Breakthrough Therapy Designation for ulixacaltamide in essential tremor","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Ulixacaltamide granted BTD for treatment of essential tremor based on Essential3 Phase 3 data.","BTD enables expedited development and regulatory review for serious condition.","Positive topline data from two pivotal Phase 3 studies supported the designation.","Essential tremor affects millions; ulixacaltamide may show substantial improvement over available therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123625,"accession_number":"0001689548-25-000116","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Praxis gets FDA nod to simplify EMBRAVE3 study; relutrigine NDA on track for early 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed to convert EMBRAVE3 from double-blind to single-arm baseline-controlled study, enrolling 30 patients (down from 40).","Primary analysis will be change from baseline in countable motor seizures; all screening patients now assigned to elsunersen.","EMBRAVE Part A (9 patients, 3:1 randomization) topline results expected in first half of 2026.","FDA confirmed that Praxis can file a New Drug Application for relutrigine in SCN2A and SCN8A DEEs in early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123624,"accession_number":"0001689548-25-000114","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Praxis gains FDA alignment for ulixacaltamide NDA; relutrigine & vormatrigine trials positive","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ulixacaltamide pre-NDA meeting with FDA completed; NDA submission expected early 2026.","Relutrigine EMBOLD study stopped early for efficacy; 53% placebo-adjusted seizure reduction (p<0.0002) over 16 weeks.","Relutrigine: 66% increase in motor seizure-free days (p=0.034); no drug-related serious adverse events.","Vormatrigine RADIANT FOS cohort (n=62): 54% median seizure reduction at 8 weeks; 11% seizure-free for entire 8-week period.","Vormatrigine POWER1 pivotal study fully enrolled; POWER2 on track for H2 2026; POWER3 monotherapy starts H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123623,"accession_number":"0001689548-25-000110","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Praxis reports Q3 net loss $73.9M; ulixacaltamide Phase 3 positive; pro forma cash ~$956M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Ulixacaltamide met primary endpoints in both Essential3 Phase 3 studies for essential tremor; pre-NDA meeting with FDA scheduled Q4 2025.","Q3 net loss $73.9M vs $51.9M YoY; R&D expenses rose to $65.8M from $41.9M.","Cash and marketable securities $389.2M at Sept 30; October public offering added ~$567M net, extending runway into 2028.","Vormatrigine POWER1 study for focal onset seizures fully enrolled; topline expected 1H 2026.","Relutrigine interim analysis for SCN2A/SCN8A DEEs planned Q4 2025; if positive, NDA submission possible early 2026."],"consensus_eps_estimate":-3.5109,"consensus_eps_actual":-9.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123622,"accession_number":"0001689548-25-000103","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA grants Type B meeting for Praxis's ulixacaltamide in Q4 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted a Type B meeting following review of Essential3 topline results for ulixacaltamide.","Meeting to occur in Q4 2025; pre-NDA meeting request was previously disclosed.","Corporate presentation updated and posted on investors.praxismedicines.com.","No financial results or guidance changes included in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123621,"accession_number":"0001104659-25-100488","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Praxis Precision Medicines raises ~$567M in underwritten public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 3,025,480 shares at $157.00 and 318,470 pre-funded warrants at $156.9999 per underlying share.","Underwriters fully exercised option for 501,592 additional shares; total net proceeds expected ~$567M.","Net proceeds to fund R&D, commercialization prep, and working capital; expected to fund operations into 2028.","Pre-funded warrants exercisable immediately with 4.99% beneficial ownership limitation (adjustable up to 19.99%).","Closing expected October 20, 2025; shares listed on Nasdaq (PRAX); pre-funded warrants not listed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123620,"accession_number":"0001689548-25-000100","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Praxis ulixacaltamide Essential3 Phase 3 meets primary endpoint: 4.3 pt mADL11 improvement vs placebo (p<0.0001)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study 1: 4.3 pt mean improvement in mADL11 at Week 8 vs 1.7 pt placebo (p<0.0001); all key secondary endpoints significant.","Study 2 randomized withdrawal: 55% maintained response on ulixacaltamide vs 33% placebo (p=0.037, OR=2.7).","Common TEAEs included constipation, dizziness, euphoric mood, brain fog; no deaths or drug-related serious AEs.","Pre-NDA meeting submitted to FDA; NDA submission planned by early 2026.","Discontinuation rates due to TEAEs: 27% ulixacaltamide vs 1.7% placebo in Study 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140304,"accession_number":"0001104659-25-087865","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Praxis terminates $250M Jefferies ATM, enters new $250M ATM with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated 2024 Sales Agreement with Jefferies effective Sept 2, 2025; no penalties.","Previously sold 1,368,176 shares for ~$86.2M gross proceeds under that agreement.","Entered new 2025 Sales Agreement with TD Cowen for up to $250M in at-the-market offerings.","TD Cowen will receive a commission of up to 3.0% of gross proceeds from sales.","New ATM will be made under existing S-3ASR registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140303,"accession_number":"0001689548-25-000094","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Praxis reports RADIANT study positive: 56.3% median seizure reduction; Q2 net loss $71.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vormatrigine in focal onset seizures (n=37): 56.3% median reduction in seizure frequency over 8 weeks; 22% achieved 100% reduction in last 28 days.","Cash and investments $446.6M at June 30, 2025, providing runway into 2028.","Q2 2025 net loss $71.1M vs $32.7M in Q2 2024; R&D expenses rose to $63.0M from $27.3M.","Relutrigine received FDA Breakthrough Therapy Designation for SCN2A and SCN8A DEEs in July 2025.","Initiated registrational studies: EMERALD (broad DEEs with relutrigine) and EMBRAVE3 (SCN2A GoF with elsunersen)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140302,"accession_number":"0001689548-25-000086","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"FDA grants Breakthrough Therapy Designation for relutrigine in SCN2A/SCN8A DEEs","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Breakthrough Therapy Designation for relutrigine in pediatric SCN2A and SCN8A DEEs.","BTD supported by positive data from EMBOLD study cohort 1 and 11-month open-label extension data.","Company initiated EMERALD study evaluating relutrigine across all DEEs.","Company entered quiet period ahead of RADIANT Phase 2 topline results expected by mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157959,"accession_number":"0001689548-25-000075","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Praxis Precision stockholders elect directors, ratify EY, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Jeffrey Chodakewitz and Merit Cudkowicz as Class II directors with 14.6M and 17.5M votes for, respectively.","Ratified Ernst & Young as independent auditor for FY2025: 18.36M for, 7,630 against.","Advisory 'say-on-pay' approved: 10.67M for (60.7%) vs 6.92M against (39.3%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157958,"accession_number":"0001689548-25-000062","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Praxis Precision reports sustained seizure reduction with relutrigine, announces Phase 3 trial design","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated EMBOLD open-label data (n=12) show sustained seizure reduction and increased seizure-free periods through 11 months of relutrigine treatment in SCN2A/SCN8A DEEs.","Announced EMERALD Phase 3 trial design: randomized, placebo-controlled, 160 patients aged 2–65 years, 16-week treatment period.","Plans to nominate development candidate for PRAX-100, an antisense oligonucleotide targeting SCN2A loss-of-function in autism, in mid-2025.","Corporate presentation furnished as Exhibit 99.1 includes program updates provided at May 2, 2025 investor event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157957,"accession_number":"0001689548-25-000056","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Praxis posts Q1 net loss of $69.3M; cash $472M, runway into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $69.3M for Q1 2025 vs $39.6M YoY; R&D spend $60.8M (up 125% YoY).","Cash & investments $472M as of March 31, 2025; no revenue recognized.","Essential3 essential tremor trial continues after futility interim; topline Q3 2025.","Vormatrigine RADIANT topline mid-2025, POWER1 H2 2025; EMERALD & EMBRAVE3 studies to start mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176351,"accession_number":"0001689548-25-000037","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Praxis Essential3 interim analysis recommends futility; studies continue to Q3 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IDMC recommended stopping Essential3 Study 1 for futility; Praxis continues both studies to completion.","Topline results for Essential3 now expected Q3 2025; NDA decision after final data.","Cash, equivalents and marketable securities of $469.5M as of Dec 31, 2024, up from $81.3M.","Net loss for Q4 2024 was $58.7M vs. $26.9M in Q4 2023; R&D spend rose to $56.3M from $18.4M.","UCB exercised option to in-license KCNT1 candidate; Praxis eligible for up to ~$100M in milestones plus royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176350,"accession_number":"0001689548-25-000021","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Praxis reports $470M cash, NDA plans for ulixacaltamide in 2025, and UCB option exercise for KCNT1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities ~$470M at Dec 31, 2024; runway into 2028.","Interim analysis of Essential3 Study 1 for ulixacaltamide in essential tremor expected Q1 2025; NDA filing planned for 2025.","UCB exercised option to license KCNT1 small molecule; Praxis eligible for up to ~$100M milestones plus tiered royalties.","RADIANT (vormatrigine) topline in H1 2025; POWER1 (vormatrigine) topline by year-end 2025.","EMBOLD cohort 2 for relutrigine on track with NDA filing expected in 2026; third RPDD received for Dravet Syndrome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193207,"accession_number":"0001689548-24-000098","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Praxis Q3 net loss $51.9M; relutrigine seizure freedom; ulixacaltamide interim Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $411.2M at Sep 30, 2024, up from $81.3M at Dec 31, 2023; net loss $51.9M vs $24.6M prior year Q3.","Relutrigine (PRAX-562): 46% placebo-adjusted seizure reduction in EMBOLD cohort 1; 30% of patients (5/15) achieved seizure freedom; registrational cohort 2 initiated.","Ulixacaltamide: interim analysis for Phase 3 Essential3 Study 1 expected Q1 2025; NDA filing anticipated in 2025; Parkinson's program to re-initiate.","Vormatrigine (PRAX-628): RADIANT topline in H1 2025 and POWER1 topline in H2 2025; pain expansion being evaluated.","R&D expenses $41.9M (up $24.6M); G&A $15.3M (up $6.6M); stock-based compensation $12.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":1090000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193206,"accession_number":"0001104659-24-108345","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Praxis Precision amends exec severance; CEO multiplier 1.75x, CFO/GC 1x","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Marcio Souza gets 1.75x base salary plus target bonus, plus prorated bonus, on change-in-control qualifying termination.","CFO Timothy Kelly and GC Alex Nemiroff get 1.0x base salary plus target bonus, plus prorated bonus, on change-in-control termination.","Outside change-in-control, CEO gets 12 months base salary continuation; CFO and GC get 9 months.","Amendments add unpaid prior year bonus and pro-rata annual bonus for executives on qualifying termination.","Accelerated vesting of time-based equity awards upon change-in-control termination; performance awards per existing plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209578,"accession_number":"0001104659-24-096035","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Praxis Precision Medicines announces positive topline results from EMBOLD study of relutrigine in SCN2A/SCN8A DEE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Placebo-adjusted reduction of 46% in countable motor seizures for relutrigine-treated patients.","5 of 16 randomized patients achieved 28-day seizure-free status on relutrigine vs. none on placebo.","Relutrigine was generally safe and well tolerated; no patients discontinued due to adverse events.","Eight patients completed ≥1 OLE period with median motor seizure reduction of 75%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209577,"accession_number":"0001689548-24-000086","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Praxis reports Q2 2024 net loss $32.7M; cash $433.8M; multiple trial milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $433.8M ($81.3M at Dec 31, 2023); runway into 2027.","Net loss $32.7M vs $34.3M YoY; R&D expense $27.3M vs $25.6M.","Ulixacaltamide Essential3 interim analysis in Q4 2024; NDA submission on track for 2025.","Relutrigine (PRAX-562) Phase 2 EMBOLD topline results expected Q3 2024.","PRAX-628 Phase 2/3 POWER1 study to start Q4 2024; RADIANT Phase 2 topline H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":788000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227682,"accession_number":"0001689548-24-000073","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Praxis Precision Medicines shareholders approve 870K share increase for 2020 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Dean Mitchell and Jill DeSimone as Class I directors for terms ending 2027.","Ratified Ernst & Young as independent auditor for FY 2024 with 15.3M votes for.","Approved amendment to 2020 Stock Plan, increasing authorized shares by 870,000 (9.1M for, 5.1M against).","Advisory vote on executive compensation passed with 10.0M for, 4.1M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227681,"accession_number":"0001689548-24-000058","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Praxis Q1 net loss $39.6M; cash $451.2M, positive PRAX-628 data; Essential3 topline H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $39.6M in Q1 2024 vs $37.5M a year ago; R&D expense $27.0M, G&A $15.3M.","Cash $451.2M at April 30, 2024, from two public offerings ($161.6M Jan, $215.8M Apr); runway into 2027.","PRAX-628 Phase 2a PPR study: 100% response; 80% complete at 15mg, 100% at 45mg; focal onset seizure studies start H2 2024 and H1 2025.","Ulixacaltamide Essential3 trial: >50K pre-screening forms, >7K referrals; topline H2 2024 to support NDA in 2025.","PRAX-562 EMBOLD study in pediatric DEEs: randomization completed; topline results expected Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":431000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246484,"accession_number":"0001104659-24-041158","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Praxis Precision Medicines prices $56.50/share offering, expected $215.6M net proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 3,318,585 shares at $56.50 and 221,238 pre-funded warrants at $56.4999; underwriters exercised option for 530,973 additional shares.","Net proceeds of ~$215.6M after discounts and expenses; closing expected April 2, 2024.","Proceeds to accelerate PRAX-628 development and continue R&D for ulixacaltamide, PRAX-562, and PRAX-222.","Company believes existing cash plus net proceeds will fund operations into 2027.","Underwriters: Piper Sandler, Guggenheim Securities, and Truist Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246483,"accession_number":"0001689548-24-000041","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Praxis reports 100% response rate in PRAX-628 Phase 2a epilepsy PPR study; plans focal onset trial H2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["15 mg cohort: 100% total response (20% partial, 80% complete); 45 mg cohort: 100% complete response.","Combined cohort: 88% complete response, 12% partial response; 8 of 9 evaluable patients responded.","Safety consistent with Phase 1; pharmacokinetic analysis confirmed therapeutic exposures.","Company plans to initiate a focal onset epilepsy efficacy study in second half of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246482,"accession_number":"0001689548-24-000035","cik":1689548,"company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Praxis: FY2023 net loss $123.3M; cash $247.6M; ulixacaltamide Phase 3 on track, PRAX-628 topline expected 1Q24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $247.6M as of Feb 29, 2024, funded by $161.7M January 2024 follow-on; runway into 2026.","FY2023 net loss $123.3M vs $214.0M in 2022; R&D expenses fell to $86.8M from $155.0M.","Essential3 Phase 3 program for ulixacaltamide (ET) has >3,000 pre-qualified referrals; enrollment due 1H24, topline 2H24.","PRAX-628 PPR study 15 mg cohort exceeded expectations; topline data expected Q1 2024; Phase 2b plan in 2H24.","Elsunersen (PRAX-222): 43% median seizure reduction in EMBRAVE Part 1; EMA PRIME designation for SCN2A DEE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9869085683.146194,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}